Germinal Multi fits one antibody sequence to many antigen variants, and its BA.2/KP.3 campaign yielded a dual-neutralizing antibody after one screening round
Antibodies often lose potency as their targets evolve, and earlier de novo design methods optimized a single paratope against one antigen structure at a time. Germinal Multi frames design of one antibody sequence against multiple antigen variants as multi-objective optimization; on cancer and viral antigens it produced antibodies that bound resistance-associated EGFR variants or neutralized both BA.2 and KP.3, with recognition extending to variants withheld from design. It also combined evolutionary forecasting with deep mutational scanning to redesign BD55-1205, restoring neutralization of the engineered escape variant XFG-Next while preserving activity against parental XFG.